Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy

References

• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487–494.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia:Results of the MRC AML12 trial. J Clin Oncol 2010;28: 586–595.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: results of the MRC AML15 trial. Blood 2009;114(Suppl. 1): Abstract 200.
   Google Scholar
• Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009;27:5397–5403.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Benner A, Hartmann F, et al. Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. Leukemia 2003;17:1521–1528.
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AM-LCG) 1992 trial. Blood 2003;101:64–70.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999;107:69–79.
   PubMed Web of Science ®Google Scholar
• Kern W, Aul C, Maschmeyer G, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998;12:1049–1055.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Fader S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818–5823.
   PubMed Web of Science ®Google Scholar
• Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000;71:238–244.
   PubMed Web of Science ®Google Scholar
• Löfgren C, Paul C, Aström M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 2004;124:474–480.
   PubMed Web of Science ®Google Scholar
• Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79:2246–2255.
   PubMed Web of Science ®Google Scholar
• Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998;91: 2722–2730.
   PubMed Web of Science ®Google Scholar
• Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007;31:1383–1388.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21: 453–461.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349: 743–752.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, et al. Use of glycosylated human recombinant G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005;106:27–34.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725–1732.
   PubMed Web of Science ®Google Scholar
• Wei GQ, Ni WM, Chiao JW, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011;4:46.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Chen YH, Huang XJ, Xu LP, et al. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors. Zhonghua Nei Ke Za Zhi 2006;45:624–627.
   PubMedGoogle Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311–2318.
   PubMed Web of Science ®Google Scholar
• Miyauchi J, Kelleher CA, Wang C, et al. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272–1278.
   PubMed Web of Science ®Google Scholar
• Inatomi Y, Toyama K, Clark SC, et al. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994;54:455–462.
   PubMed Web of Science ®Google Scholar
• Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004;72:89–106.
   PubMed Web of Science ®Google Scholar
• Kutlay S, Beksac M, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and its effect on therapy in acute myeloid leukemia. Leuk Lymphoma 2003;44:791–795.
   PubMed Web of Science ®Google Scholar